DEDilek Çuhadar Erçelebi

Dilek Çuhadar Erçelebi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dilek Çuhadar Erçelebi has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of patch test outcomes in adult patients at a tertiary allergy center

    by Gürgün Tuğçe Vural Solak, Kurtuluş Aksu, Dilek Çuhadar, Şenay Demir, Özge Göktürk, Yavuz Karahan, Barış Uslu

    Aims: Patch testing is a standard procedure in the diagnosis of allergic contact dermatitis. It is based on the principle that the reaction reappears after contact with the allergen. The aim of our study is to evaluate allergen sensitivity in our region and the factors affecting it. Methods: Patients who underwent at least one patch test from the European Baseline Series (EBS), cosmetic series or dental series at our clinic between January 2024 and July 2025 were included in the study. The patients' age, gender, presence of atopy, accompanying allergic diseases, body areas suspected of dermatitis, and patch test results were retrospectively evaluated. Results: Of the 115 patients included in the study, 73.9% were female, with a median age of 45 (min-max: 18-80). In patients undergoing EBS (n=41), nickel (II) sulphate and cobalt (II) chloride were the most frequently detected allergens. In the cosmetic series patch test group (n=55), gallate mix and thimerosal were most frequently detected, while in the dental series patch test group, nickel (II) sulphate and sodium tetrachloropalladate (II) hydrate were predominant. The median age of patients with multiple allergen sensitivities was significantly lower than that of patients with single allergen sensitivities (p=0.005). Conclusion: Our study found that regional allergen sensitivity was consistent with data in the literature. Our study shows that multiple allergen positivity is more common in young patients and emphasises the importance of patch testing in identifying relevant allergens and guiding clinical treatment.

  • Open Access

    Etoposide hypersensitivity reactions and outcomes of desensitizations in immediate-type hypersensitivity reactions

    by Gözde Köycü Buhari, Sakine Nazik Bahçecioğlu, Selcan Gültuna, Özgür Akkale, Hatice Çelik Tuğlu, Onur Telli, Fatma Dindar Çelik, Melis Yağdıran, Dilek Çuhadar, Şenay Demir, et al.

    Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten (25.6%) patients had known other drug allergies and three (7.7%) patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle (n=29, 74.4%). Ten (25.4%) patients had hypersensitivity reactions at the first application of etoposide. Thirty (76.9%) patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 (53.3%) and moderate in 14 (46.7%) patients. Most common symptoms were erythema in 29 (96.7%), dyspnea in 13 (43.3%), chest tightness in 8 (26.7%), discomfortness in 7 (23.3%), and hypertension in 6 (20%). Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 (11.1%) patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

  • Open Access

    Safety of partial selective COX-2 inhibitors in patients with cross-reactive NSAID hypersensitivity and factors affecting safety

    by Gözde Köycü Buhari, İlkay Koca Kalkan, Buket Başa Akdoğan, Hale Ateş, Özlem Özdedeoğlu, Süleyman Türkyılmaz, Dilek Çuhadar, Kurtuluş Aksu, Ferda Öner Erkekol

    Aims: Partial selective COX-2 inhibitors, such as nimesulide, or meloxicam are tolerated by the majority of the patients with cross-reactive NSAID hypersensitivity. This study aimed to obtain more information about the safety of partial selective COX-2 inhibitors; nimesulide and meloxicam in non-immunologic type, cross-reactive NSAID hypersensitivity and to detect risk factors for intolerance to these drugs. Methods: This is a retrospective study of patients with suggestive of cross-reactive NSAID hypersensitivity who admitted to our clinic over a period of 10 years. Patients who had a reliable history of immediate type NSAIDs hypersensitivity with at least 2 chemically unrelated class and/or positive ASA provocation test and who underwent alternative drug provocation test with partial selective COX-2 inhibitors (nimesulide and/or meloxicam) were included to study. Patients’ demographics, comorbidities, atopy status, duration of NSAID hypersensitivity, total number of reactions, reaction grades, clinical phenotypes, pulmonary function test parameters and results of alternative drug provocation test results are recorded. Patients with and without reactions during alternative provocation tests with nimesulide and/or meloxicam were compared in terms of these data. Results: A total of 560 patients were included in the study, 378 (67.5%) of them were female. Allergic comorbidities were detected in 394 (72.6%) patients. Asthma, other drug allergies and nasal polyp were the most common comorbidities. Alternative drug provocation test positivity with nimesulide and/or meloxicam was detected in 50 of 560 (8.9%) patients. Provocation test positivity was 33/541 (6.1%) with nimesulide, 30/517 (5.8%) with meloxicam and 13/498 (2.3%) with both nimesulide and meloxicam. Duration of NSAID hypersensitivity was shorter and allergic comorbidities, asthma, nasal polyp and the coexistence of asthma and nasal polyp were more common in patients with a positive provocation test. Conclusion: The partial selective COX-2 inhibitors nimesulide and meloxicam are well tolerated alternatives in patients with cross-reactive NSAID hypersensitivity. Hypersensitivity to these drugs is significantly higher in patients with asthma and/or nasal polyp than other group of cross-reactive NSAID hypersensitive patients and also in patients with a shorter duration of NSAID hypersensitivity.

  • Open Access

    Characteristics of adverse reactions due to subcutaneous allergen immunotherapy applied between 2011-2021: Single center experience

    by Gürgün Tuğçe VURAL SOLAK, Kurtuluş AKSU, Yavuzalp Solak, Şenay Demi̇r, Dilek Çuhadar Erçelebi̇, Gözde Köycü Buhari̇, Sakine Nazi̇k Bahçeci̇oĞlu, İlKay Koca Kalkan, Hale Ateş, Selma Yeşi̇lKaya

    The aim of this study was to elucidate the incidence of local, large local and systemic reactions after subcutaneus immunotherapy (SCIT) injections in our clinic and to determine the characteristic features of these adverse reactions. A total of 6000 SCIT injections administered to 163 patients between January 2011 and December 2021 were retrospectively evaluated. The study population consisted of patients with allergic rhinoconjunctivitis who underwent SCIT due to pollen, house dust mite or cat allergy, or patients who underwent SCIT due to venom allergy. Demographic characteristics of the patients, diagnoses, allergen sensitivities, immunotherapy protocol applied, adverse reactions, and the characteristics of these reactions were recorded. Totally, 163 patients with a mean age of 36.8 ± 12.7 years were enrolled in this research. Sex distribution was as follows: 55.2% (n= 90) were females. During the study, 218 allergic reactions were detected in 83 patients. The incidence of adverse reactions per injection was 3.6%. The probability of developing an adverse reaction in a patient during the entire subcutaneous immunotherapy was 53.9%. Of the adverse reactions that developed, 94 (43.1%, n= 47) were observed locally while 56 (25.7%, n= 40) were large local reactions, and 68 (31.2%, n= 30) were systemic. Incidence of adverse reactions per injection were 1.5%, 0.9%, and 1.1% for local reaction, large local reaction, and systemic reaction, respectively. The results of this analysis elaborated that subcutaneous immunotherapy is a safe and tolerable treatment modality. However, before initiating treatment, the benefits and risks should be evaluated. The risk of systemic reactions is quite low, but fatal anaphylaxis can occur, so physicians need to be aware of the potential risks.


  • Successful desensitization under antihistamine suppression in a case with urticaria due to osimertinib

    by Gürgün Tuğçe Vural Solak, Kurtuluş Aksu, Musa Topel, Dilek Çuhadar Erçelebi, Selma Yeşilkaya, Şenay Demir, Gözde Köycü Buhari, İlKay Koca Kalkan, Hale Ateş, Sakine Nazik Bahçecioğlu

    Introduction: Osimertinib is an approved therapy for patients with a Thr790met (T790M) mutation diagnosed with non-small cell lung cancer (NSCLC) that progresses during epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy. However, in 7–13% of patients, drug-related side effects lead to discontinuation of osimertinib treatment. In such cases, osimertinib desensitization is a treatment option that can be considered. Case report: A 59-year-old female patient, who was followed up with the diagnosis of stage 4 NSCLC, was consulted to the allergy clinic because of urticaria. The patient developed urticaria plaques 20 h after the third dose of osimertinib tablet. Management & outcome: With the diagnosis of osimertinib-induced urticaria, desensitization was planned for the patient. Treatment was started with a dose of 0.1 mg/day osimertinib. The procedure was completed in approximately 50 days, and a dose of 80 mg/day was reached with antihistamine suppression. Discussion: Here, a successful osimertinib desensitization in a patient with a history of osimertinib-related type 1 allergic reaction is reported. Osimertinib desensitization is a treatment option that should be considered in cases where treatment has to be ceased due to drug-related side effects.


  • Mycobacterium abscessus enfeksiyonu yönetimi: Makrolid ve kinolon desensitizasyonu

    by Kurtuluş Aksu, Dilek Çuhadar Erçelebi, Şeref Özkara, Süleyman Türkyılmaz, İlkay Koca Kalkan, Özlem Özdedeoğlu, Buket Başa Akdoğan, Hale Ateş, Gözde Köycü Buhari

    Antibiotic hypersensitivity reactions can lead to marked morbidity, mortality and inadequate treatment options. Mycobacterium abscessus infection is a difficult management system for clinicians since it most commonly involves the lungs, progresses if untreated, and the organism is resistant to many antibiotics, as well as the agents used in treatment can cause undesirable side effects. Although macrolides are one of the most reliable antibiotic groups in terms of allergic reactions, early type hypersensitivity reactions against macrolides, one of the main antibiotics used in the treatment of Mycobacterium abscessus lung disease, may make the treatment management of the disease difficult. Due to the rapid increase in the use of quinolone in recent years, the frequency of developing allergic reactions with these agents also increases. In cases where antibiotic hypersensitivity is detected, the use of the responsible agent should be avoided, but desensitization may be necessary in cases without different treatment options. In this study, it was aimed to present a case of successful desensitization with clarithromycin and moxifloxacin in a patient who was diagnosed with Mycobacterium abscessus lung disease and developed anaphylaxis with clarithromycin and moxifloxacin after treatment was initiated.


  • COVID-19 in patients with severe asthma using biological agents

    by Kurtuluş Aksu, Şenay Demir, Musa Topel, Selma Yeşilkaya, Hale Ateş, İlkay Koca Kalkan, Ali Öncül, Dilek Çuhadar Erçelebi, Süleyman Türkyılmaz

    As the COVID-19 pandemic continues, case reports have been published where patients with severe asthma using biological agents survived with a mild course of illness and encouraged the continuation of biological therapies in patients with severe asthma. However, contrary to previous information, a more severe course of COVID-19 has recently been reported in severe asthmatics using biological therapy compared to the general population. To evaluate the COVID-19 rate and disease severity in severe asthmatics using biological agents. A retrospective study was conducted in patients with severe asthma treated with biological agents. Data concerning whether the subjects had contracted COVID-19 and the severity of the disease were evaluated. Eihgty-four severe asthmatics using biological agents (omalizumab or mepolizumab) aged 48.3 +/- 10.6 years (mean +/- standard deviation) with female/male ratio: 53 (63.1%)/31 (36.9%) were included in the study. Among participants 13 (15.5%) had contracted COVID-19. The course of COVID-19 was mild in five (38.5%) and moderate in eight patients (61.5%), while none of the patients had a severe course of COVID-19. Mechanical ventilation or intensive care follow-up was not required in any of the six patients (46.2%) who were treated as inpatients. All participants survived COVID-19 in full recovery and no deaths occurred in the cases. A higher rate of COVID-19 was found in patients with severe asthma using biologics compared to those reported in previous reports. However, all patients with COVID-19 have a mild to moderate disease course.